Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ADC Therapeutics SA

Latest From ADC Therapeutics SA

Stock Watch: Exploring Biotech’s Route Through Bubble And Wilderness

Biotech has always been a volatile sector, and it is important for investors to recognize the phases its stocks go through. In particular, the journey through the post-bubble wilderness can be a protracted affair.

Stock Watch Financing

ADC Therapeutics To Wind Up Zynlonta Study In Frail Patients After Deaths

The company had hoped its antibody drug conjugate could help frail and elderly B-cell lymphoma patients ineligible for chemotherapy, but the trial will now close following patient deaths.

Companies Research & Development

ADC’s Label-Expansion Study For Zynlonta Halted For Respiratory Safety

A Phase II study in a frail, older lymphoma population has seen seven respiratory-related deaths along with five other serious adverse events, but so far Zynlonta has been deemed not related to the AEs.

Clinical Trials Drug Safety

Funding Clicks Into Place For Tagworks

Backed by an international syndicate of investors including Novartis and Ysios Capital, Tagworks has raised a healthy sum to advance its proprietary click-to-release platform technology and take its first click-cleavable antibody-drug conjugate into the clinic.

Financing Cancer
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • ADC Therapeutics Sarl
    • ADC Therapeutics S.A.